Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

5 Reasons Not to Worry This Week: Groupon Inc (GRPN), MAKO Surgical Corp. (MAKO)

Page 1 of 2

It’s not a perfect world out there for investors, but things may be starting to get better.

I recently went over some of the companies that are expected to post lower quarterly profits when they report this week. Thankfully, they’re the exceptions and not the rule.

MAKO Surgical Corp. (NASDAQ:MAKO)Let’s go over some publicly traded companies that are expected to stand tall this week by posting year-over-year improvement on the bottom line.

Company Latest-Quarter EPS (estimated) Year-Ago Quarter EPS
Questcor Pharmaceuticals (NASDAQ:QCOR) $1.00 $0.47
MAKO Surgical Corp (NASDAQ:MAKO) ($0.11) ($0.14)
Groupon Inc (NASDAQ:GRPN) $0.03 ($0.02)
Monster Beverage Corp (NASDAQ:MNST) $0.41 $0.35
OmniVision Technologies Inc. (NASDAQ:OVTI) $0.41 $0.13

Source: Thomson Reuters.

Clearing the table
Let’s start at the top with Questcor. The drugmaker’s multifaceted Acthar gel isn’t cheap at $23,000 per vial, and its marketing practices are being probed by the U.S. government. That’s been a dark cloud over the stock, but value investors are starting to nibble at Questcor here at less than eight times this year’s projected profitability and a healthy 2.6% yield.

Those valuations may not be sustainable if Questcor has to slash prices or if insurance companies stop offering coverage, but that didn’t stop analysts at Mizuho from upgrading the stock last week. Channel checks at Mizuho are turning up a welcome decline in reimbursement concerns.

Wall Street sees profitability more than doubling in Tuesday’s report, and you don’t see that too often with stocks fetching single-digit earnings multiples.

MAKO is the top dog in orthopedic robotics. It was certainly a dog last summer when the shares plummeted on weak sales of its RIO platform, even though the systems that were already in operation were still being used often.

Things haven’t improved for the profitless MAKO. The stock hit a fresh three-year low last month and continues to trade 75% off last year’s high.

Even the more bullish analysts don’t see MAKO turning a profit until next year, but the good news here is that Wall Street’s eyeing a much smaller deficit this time around. Yes, they also see a problematic year-over-year decline in revenue, but nobody’s perfect.

Groupon may be a surprising name on this list. The daily-deals leader that went public with plenty of hype at $20 two years ago has been continuously trading in the single digits since this past summer.

Then again, things may not be so bad here. For starters, the stock has gone on to more than double since bottoming out in November. Looking out to Wednesday’s report, analysts see the flash-sale giant reversing a year-ago loss with a reasonable profit.

Monster Beverage came under selling pressure late last year when regulators and a pair of congressmen voiced their concerns about the health risks of the company’s flagship energy drink. Despite the tumble, investors may be surprised that shares of Monster actually gained ground in 2012, keeping its four-year streak of higher closes intact.

Have the investigations and accusations eaten into Monster’s sales? We’ll get a great snapshot when Monster reports on Wednesday. The fundamentals appear to still be there. Analysts see revenue and earnings per share climbing 18% and 17%, respectively.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!